頭頸部鱗狀細胞癌市場：KOL 洞察

本報告對不斷發展的頭頸部鱗狀細胞癌（HNSCC）治療前景進行調查分析，重點關注新治療方法和臨床試驗結果的整合。主要發現包括Merck的Keytruda的預期擴張和 Merus 的bispecific antibody petosemtamab的潛力。該公司也探索 Bicara 的bifunctional antibody ficerafusp alfa的早期資料，以及 Summit/Akeso 的bispecific ivonescimab的轉化潛力。從關鍵意見領袖那裡獲得有關這些發展及其對未來 HNSCC 治療的影響的寶貴見解。

報告內容

• 繼 KEYNOTE-689 試驗成功後，KOL 想知道Merck的Keytruda 能否成為局部晚期（LA）HNSCC 圍手術期治療的新標準
• Merus 的抗 EGFR/LGR5 雙特異性抗體與 Keytruda 聯合使用的早期資料顯示，在一線復發/轉移性（R/M）HNSCC 治療中具有很高的反應率，但 KOL 對這些資料將轉化為成功的III 期試驗有多樂觀？
• Summit 和 Akeso 展示了抗 PD-1/VEGF 雙特異性抗體 ivonescimab 在肺癌治療中的令人印象深刻的臨床資料，但專家如何評估其在 HNSCC 治療中的潛力？
• Coherus/君實的PD-1 抑制劑 Loqtorzi（特瑞普利單抗）已獲得 FDA 和 EMA 批准用於治療 R/M 鼻咽癌（NPC），但 KOL 對這款 PD-1 抑制劑的中長期使用有何期待？
• KOL 如何解讀 Cue Biopharma 針對 R/M HNSCC 患者的CUE-101 第2 期資料，以及他們如何評估這種基於 IL-2 的T 細胞接合劑成功的可能性？ 治療性疫苗在未來的HNSCC 治療中可能扮演什麼角色？

主要品牌

This comprehensive report provides an in-depth analysis of the evolving treatment landscape for head and neck squamous cell carcinoma (HNSCC), focusing on the integration of novel therapies and clinical trial outcomes. Key findings include the anticipated expansion of Merck's Keytruda and the potential of Merus' bispecific antibody petosemtamab. This report also explores the promising early data for Bicara's bifunctional antibody ficerafusp alfa and the transformative potential of Summit/Akeso's bispecific ivonescimab. Gain valuable insights from key opinion leaders into these developments and their implications for future HNSCC treatment.

Key Questions Answered:

• 1. Given the success of the KEYNOTE-689 study, do KOLs see Merck & Co.'s Keytruda becoming a new standard of care in the perioperative setting for the treatment of locally advanced (LA)-HNSCC?
• 2. Early data for Merus' anti-EGFR/LGR5 bispecific antibody in combination with Keytruda indicate high response rates in first-line recurrent/metastatic (R/M) HNSCC, but how optimistic are KOLs that this could translate into a positive Phase III trial?
• 3. While Summit and Akeso have shown impressive clinical data for their anti-PD-1/VEGF bispecific antibody ivonescimab in lung cancer, how do experts weigh up its prospects in HNSCC?
• 4. With the FDA and EMA approvals of Coherus/Junshi's PD-1 inhibitor Loqtorzi (toripalimab) in R/M nasopharyngeal carcinoma (NPC), what are KOL expectations for this PD-1 inhibitor's use in the mid-to-long term?
• 5. How do KOLs interpret the Phase II data for Cue Biopharma's CUE-101 in patients with R/M HNSCC, and how do they rate this IL-2-based T-cell engager's prospects for success?
• 6. What is the likelihood that therapeutic vaccines will have a role in the future treatment of HNSCC?

Key Brands:

Partial List of Participating Experts:

• Professor, Medical Oncologist specialising in head and neck cancer, University of California, USA
• Director of Head and Neck Medical Oncology and Professor of Medicine at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, USA
• Professor of Medicine and Head and Neck Oncologist, Duke Cancer Institute, USA
• Head of Medical Oncology, Institut Catala d'Oncologia (ICO), Spain
• Professor of Medical Oncology, Humanitas University, Italy
• Consultant Clinical Oncologist and Honorary Reader, Royal Marsden Hospital and the Institute of Cancer Research, UK

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.